David Hoang
Stock Analyst at Deutsche Bank
(1.83)
# 3,031
Out of 4,834 analysts
38
Total ratings
37.93%
Success rate
-9.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $31.21 | +66.61% | 2 | Mar 27, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $124 → $99 | $35.27 | +180.69% | 6 | Mar 19, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $29.53 | +126.89% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $37.20 | +198.39% | 1 | Feb 11, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $55 | $34.17 | +60.96% | 2 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $14.16 | +118.93% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $15.82 | +310.87% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $107.22 | +64.15% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $8.89 | +34.98% | 1 | Feb 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $17.60 | +30.68% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $120.25 | +31.39% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.01 | +593.07% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $8 | $6.61 | +21.03% | 1 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.59 | +517.76% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.28 | +387.80% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $283.40 | -22.37% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $15.34 | +421.51% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $1.05 | +185.71% | 1 | Dec 7, 2022 |
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $31.21
Upside: +66.61%
Sarepta Therapeutics
Mar 19, 2025
Maintains: Hold
Price Target: $124 → $99
Current: $35.27
Upside: +180.69%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $29.53
Upside: +126.89%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $37.20
Upside: +198.39%
Harmony Biosciences Holdings
Feb 11, 2025
Initiates: Buy
Price Target: $55
Current: $34.17
Upside: +60.96%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $14.16
Upside: +118.93%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $15.82
Upside: +310.87%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $107.22
Upside: +64.15%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $8.89
Upside: +34.98%
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $17.60
Upside: +30.68%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $120.25
Upside: +31.39%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.01
Upside: +593.07%
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $6.61
Upside: +21.03%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $2.59
Upside: +517.76%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.28
Upside: +387.80%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $283.40
Upside: -22.37%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $15.34
Upside: +421.51%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $1.05
Upside: +185.71%